Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UQPZX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC26
|
|||||
| Synonyms |
WO2023232144A1ADC26
Click to Show/Hide
|
|||||
| Organization |
CANWELL BIOTECH LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.59
|
|||||
| Structure |
|
|||||
| Antibody Name |
Avelumab
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death 1 ligand 1 (CD274)
|
Antigen Info | ||||
| Payload Name |
WO2025015586A1, ADC22, Payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
4- ((S)-2- ((S)-2- (6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl (4- ((4-amino-2-butyl- 7- (dimethylphosphoryl)-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)carbamate
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) | > 50% | Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC26 was tested in mouse M38 CRC model in C57BL/6 mice, 3 mg/kg, QWx3, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
References